Noxilizer

Noxilizer

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $40M

Overview

Noxilizer is a private company specializing in a novel nitrogen dioxide (NO2) gas sterilization platform for the life sciences industry. Its core innovation is an ultra-low temperature (10-30°C), surface-level sterilization process that addresses critical challenges with sensitive products like prefilled syringes, drug-device combinations, and sensors, where traditional methods like ethylene oxide (EO) or steam can damage products. The company operates through a dual business model of selling proprietary sterilization equipment and offering contract sterilization services, with validation projects underway with several biopharma clients for commercial products. Noxilizer's technology is positioned as a safer, faster, and more product-friendly alternative to established sterilization methods.

Infectious Disease

Technology Platform

Proprietary ultra-low temperature (10-30°C) nitrogen dioxide (NO2) gas sterilization technology for surface sterilization of temperature-sensitive medical products.

Funding History

3
Total raised:$40M
Debt$5M
Series B$25M
Series A$10M

Opportunities

The rapid growth of biologics and temperature-sensitive drug-device combination products creates a large, underserved market for gentle sterilization.
Increasing regulatory and environmental scrutiny of ethylene oxide (EO) sterilization presents a major substitution opportunity.
The trend towards in-house manufacturing and supply chain control favors sales of Noxilizer's equipment.

Risk Factors

Market adoption is slow due to the entrenched nature of traditional sterilization methods and the high burden of product-specific validation.
Regulatory pathways, while established, require extensive client-by-client work.
Competition from large, established sterilization service providers who could develop similar technologies poses a threat.

Competitive Landscape

Noxilizer competes primarily against established sterilization methods: ethylene oxide (EO), steam autoclaving, gamma radiation, and vaporized hydrogen peroxide (VHP). Its key advantage is ultra-low temperature and surface-only action for sensitive products. It faces competition from other emerging low-temperature technologies and from large contract sterilizers (e.g., Steris, Cantel Medical) that offer a broad suite of methods and global scale.